Here’s my summary of new data to look forward to from IAS 2019.
Why IAS 2019 data provided me with new tools for my practice and a sense of hope that we can beat HIV.
Patient-reported outcomes on long-acting injectable cabotegravir plus rilpivirine reinforce high treatment acceptance and satisfaction. Here’s my take on what this means for patients and practice.
Download slide highlights of key studies addressing current issues in HIV care, as reported at this important annual conference.
Listen to downloadable audio from a live Webinar reviewing the most clinically relevant new HIV data on NTD risk in pregnancy, PrEP, first-line therapy, and switch strategies.